Crystalline modification of...

C - Chemistry – Metallurgy – 07 – C

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07C 229/60 (2006.01) A61K 31/245 (2006.01) C07C 227/42 (2006.01)

Patent

CA 2091686

A novel crystalline modification of 2-dimethylamino- ethyl-n-butylaminobenzoate hydrochloride is characterized by a single endothermal effect of melting at 148.6~0.3°C and the following values of interplanar spacings d and relative intensities of reflections I: d, .ANG. I d, .ANG. I 26.I40 3 2.824 4 I2.755 I00 2.798 2 8.538 27 2.762 I 6.380 6 2.744 2 6.II7 2 2.678 2 5.644 6 2.63I I 5.49I I2 2.570 I 5.096 56 2.534 I 4.874 I7 2.5I4 I 4.486 I0 2.454 I 4.244 I5 2.4I9 I 4.4I8 7 2.346 I 4.I37 I 2.308 I 4.00I 5 2.256 I 3.949 3 2.232 I 3.828 5 2.I66 I 3.585 3 2.008 I 3.5I5 7 I.953 2 3.427 3 I.69I I 3.34I 3 I.584 I 3.3I0 3 3.I70 3 3.I56 4 3.I49 4 d , .ANG. I d, .ANG. I 3.064 I 2.979 2 2.944 I 2.903 I A method for production of said compound residing in that a solution of 2-dimethylaminoethyl-n-butylaminobenzoate hydrochloride of polymorphic form in water or organic solvent, or in their mixture, is cooled by a cooling agent at a rate of no less than 8°C/min till complete crystallization of the solution with subsequent drying of obtained crystals. Compound of the invention has a local anaesthetic activity and is an active principle of a pharmaceutical preparation for anaesthesia of eyes (content of active principle is from 0.05 to 0.5% by mass).

Une nouvelle modification cristalline du chlorhydrate du n-butylaminobenzoate de 2-diméthylaminoéthyle est caractérisée par un seul effet endothermique de la fusion à 148,6 0,3 degrés C et par les valeurs suivantes de distances réticulaires d et d'intensités relatives des réflexions I: d, .ANG. I d,.ANG. I 26.I40 3 2.824 4 I2.755 I00 2.798 2 8.538 27 2.762 I 6.380 6 2.744 2 6.II7 2 2.678 2 5.644 6 2.63I I 5.49I I2 2.570 I 5.096 56 2.534 I 4.874 I7 2.5I4 I 4.486 I0 2.454 I 4.244 I5 2.4I9 I 4.4I8 7 2.346 I 4.I37 I 2.308 I 4.00I 5 2.256 I 3.949 3 2.232 I 3.828 5 2.I66 I 3.585 3 2.008 I 3.5I5 7 I.953 2 3.427 3 I.69I I 3.34I 3 I.584 I 3.3I0 3 3.I70 3 3.I56 4 3.I49 4 d , .ANG. I d, .ANG. I 3.064 I 2.979 2 2.944 I 2.903 I. Une méthode permettant de produire ledit composé et comportant le refroidissement, par un agent refroidissant, d'une solution de chlorhydrate de n-butylaminobenzoate de 2-diméthylaminoéthyle, sous forme polymorphe, dans de l'eau ou dans un solvant organique, à un taux d'au moins 8 degrés C par minute, jusqu'à cristallisation complète de la solution, puis séchage ultérieur des cristaux obtenus. Le composé visé par l'invention possède une action anesthésique locale et constitue l'ingrédient actif d'une préparation pharmaceutique (contenant de 0,05 à 0,5 % en masse de l'ingrédient actif) servant à l'anesthésie des yeux.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Crystalline modification of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystalline modification of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline modification of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1445371

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.